Estimated frequency and economic burden of incident fragility fractures during 2023 in Mexico.

Autor: Carlos-Rivera F; Pharmacoeconomics Department, AHS Health Consulting, S.A.S. de C.V., Huixquilucan, State of Mexico, Mexico. fernando.carlos@ahs-mex.com., Guzmán-Caniupan JA; Access Department, AHS Health Consulting, S.A.S. de C.V., Huixquilucan, State of Mexico, Mexico., Camacho-Cordero LM; Health Economics Department, Mexico City, Amgen Mexico, Mexico., Aubry de Maraumont T; Head Value & Access Department, Mexico City, Amgen Mexico, Mexico., Soria-Suárez N; Head Therapeutic Area Bone, Mexico City, Amgen Mexico, Mexico.
Jazyk: angličtina
Zdroj: Archives of osteoporosis [Arch Osteoporos] 2024 Nov 07; Vol. 19 (1), pp. 109. Date of Electronic Publication: 2024 Nov 07.
DOI: 10.1007/s11657-024-01468-2
Abstrakt: Epidemiologic and economic data regarding osteoporotic fractures in Mexico is scarce and mostly outdated. Through a model, we estimated the incidence and costs of osteoporotic fractures in adults ≥ 50 years old in Mexico during the year 2023. Results showed that these events are both frequent and costly, leading to a considerable economic impact.
Purpose: Osteoporosis and its fractures impose a high clinical and economic burden. The objective of this analysis was to estimate the frequency and costs owing to incident fragility fractures (FFs) during the year 2023 in Mexico.
Methods: This is an incidence-based cost-of-illness study. The target population is adults ≥ 50 years old sustaining a fracture related to osteoporosis (caused by a fall on the same level). The model estimates the costs and productivity losses associated with their treatment within 1 year post-fracture. National epidemiologic databases supplemented with information, derived from literature when appropriate, were used to estimate the frequency of new FFs during 2023 in the study population. Resource use included surgical and non-surgical inpatient or ambulatory care the patients received immediately after fracture plus the outpatient physiotherapy post-discharge and the eventual follow-up with a specialist who may prescribe pharmacotherapy. Sick days taken in employed patients were estimated from the literature. Local unitary costs of services and drugs for both public and private settings as well as average income in those occupied were applied. All costs are reported in Mexican pesos (MXN) from 2023.
Results: The model estimated a total of 229,239 FFs, among which 63% were classified as a major osteoporotic fracture, including 53,842 and 41,459 fractures located at the hip and vertebral, respectively. The total costs were estimated at 15,593 million MXN; most of them (75.2%) were attributable to acute-phase care.
Conclusions: Fragility fractures represent a serious health problem for Mexico. Better preventive/therapeutic strategies may help to mitigate their significant financial toll.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: